What is the prevalence of Carcinoid Syndrome?

TL;DR: Carcinoid syndrome is a rare condition occurring in approximately 8% to 35% of patients with neuroendocrine tumors (NETs), with an estimated global prevalence of roughly 1 to 2 cases per 100,000 people. Because many neuroendocrine tumors remain asymptomatic or are misdiagnosed, the true prevalence of carcinoid syndrome is likely higher than current clinical data suggests.

How common is Carcinoid Syndrome?

Carcinoid syndrome is classified as a rare disease. While neuroendocrine tumors themselves are becoming more frequently diagnosed, the development of full-blown carcinoid syndrome—characterized by flushing, diarrhea, and heart valve damage—is relatively uncommon. Current estimates suggest an incidence rate of approximately 1 to 2 per 100,000 individuals per year. It is important to note that these figures are estimates; because many cases go unrecognized for years, the actual burden of the disease may be underrepresented in medical literature.

Does Carcinoid Syndrome affect specific demographics?

Carcinoid syndrome typically manifests in adults between the ages of 50 and 60, though it can occur at any age. Current data suggests there is no significant gender predisposition, as both males and females are affected at similar rates. While there are no clear geographic or ethnic "hotspots," the rise in detection is often attributed to improved imaging and awareness in developed healthcare systems. At DiseaseMaps.org, we have observed a diverse group of 49 individuals living with carcinoid syndrome who share their unique experiences, highlighting that this condition crosses all demographic lines.

Why is accurate data for Carcinoid Syndrome difficult to obtain?

Several factors complicate our understanding of the prevalence of carcinoid syndrome:

• Asymptomatic progression: Many neuroendocrine tumors do not secrete the hormones required to trigger the syndrome until they have metastasized to the liver.


• Diagnostic delays: Symptoms like chronic diarrhea are often misattributed to Irritable Bowel Syndrome (IBS), delaying a formal diagnosis of carcinoid syndrome by months or years.


• Reporting limitations: Because it is a secondary condition arising from primary tumors, it is sometimes under-coded in hospital and cancer registry databases.

Next steps

• Consult an oncologist or endocrinologist specializing in neuroendocrine tumors to discuss your specific symptoms.


• Join our community of 49 members at DiseaseMaps.org to connect with others navigating a diagnosis of carcinoid syndrome.


• Request a referral to a high-volume neuroendocrine tumor center for specialized diagnostic testing, such as 24-hour urine 5-HIAA tests.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Carcinoid syndrome overview.


• Orphanet: Rare disease database entry for malignant carcinoid syndrome.


• The Neuroendocrine Cancer Awareness Network (NCAN): Patient resources and clinical data.


• PubMed/NCBI: "Epidemiology of Neuroendocrine Tumors and Carcinoid Syndrome" (Systematic Review).